ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
作者信息
Wu J, Meng F, Ying Y, Peng Z, Daniels L, Bornmann W G, Quintás-Cardama A, Roulston D, Talpaz M, Peterson L F, Donato N J
出版信息
Leukemia. 2010 Apr;24(4):869-72. doi: 10.1038/leu.2009.300. Epub 2010 Jan 28.
Abstract
摘要
相似文献
1
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
Leukemia. 2010 Apr;24(4):869-72. doi: 10.1038/leu.2009.300. Epub 2010 Jan 28.
2
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Oncotarget. 2012 Dec;3(12):1557-65. doi: 10.18632/oncotarget.692.
3
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.
Leukemia. 2010 Jul;24(7):1375-8. doi: 10.1038/leu.2010.107. Epub 2010 May 27.
4
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980.
5
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Leuk Lymphoma. 2011 Nov;52(11):2139-47. doi: 10.3109/10428194.2011.591013. Epub 2011 Jun 30.
6
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
J Cancer Res Clin Oncol. 2012 Feb;138(2):203-12. doi: 10.1007/s00432-011-1086-x. Epub 2011 Nov 17.
7
An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Int J Lab Hematol. 2011 Apr;33(2):176-81. doi: 10.1111/j.1751-553X.2010.01267.x. Epub 2010 Oct 4.
8
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Blood. 2007 Dec 1;110(12):4055-63. doi: 10.1182/blood-2007-07-102061. Epub 2007 Aug 24.
9
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Blood. 2007 May 1;109(9):4006-15. doi: 10.1182/blood-2006-09-045039. Epub 2007 Jan 11.
10
AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.
Chem Biol Drug Des. 2010 Feb;75(2):223-7. doi: 10.1111/j.1747-0285.2009.00911.x. Epub 2009 Dec 17.
引用本文的文献
1
The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance.
Chem Sci. 2024 Jul 13;15(33):13130-13147. doi: 10.1039/d4sc01088d. eCollection 2024 Aug 22.
2
Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Cancer Res. 2018 Oct 15;78(20):5793-5807. doi: 10.1158/0008-5472.CAN-18-0195. Epub 2018 Aug 28.
3
The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Cancer J. 2016 Jan-Feb;22(1):40-50. doi: 10.1097/PPO.0000000000000165.
4
Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.
ACS Chem Biol. 2015 Jan 16;10(1):175-89. doi: 10.1021/cb5008376. Epub 2014 Dec 23.
5
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3550-5. doi: 10.1073/pnas.1321173111. Epub 2014 Feb 18.
6
Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.
PLoS One. 2013 Nov 18;8(11):e78780. doi: 10.1371/journal.pone.0078780. eCollection 2013.
7
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells.
Blood. 2011 Dec 8;118(24):6399-402. doi: 10.1182/blood-2011-01-332783. Epub 2011 Oct 21.
8
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.
Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12469-74. doi: 10.1073/pnas.1005114107. Epub 2010 Jun 28.
本文引用的文献
1
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.
2
Metabolism and disposition of dasatinib after oral administration to humans.
Drug Metab Dispos. 2008 Jul;36(7):1357-64. doi: 10.1124/dmd.107.018267. Epub 2008 Apr 17.
3
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Blood. 2008 Jul 1;112(1):53-5. doi: 10.1182/blood-2007-11-123950. Epub 2008 Apr 10.
4
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Blood. 2008 Apr 1;111(7):3821-9. doi: 10.1182/blood-2007-08-109330. Epub 2008 Jan 30.
5
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Blood. 2007 Dec 1;110(12):4055-63. doi: 10.1182/blood-2007-07-102061. Epub 2007 Aug 24.
6
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Blood. 2007 Apr 15;109(8):3470-8. doi: 10.1182/blood-2006-02-005579. Epub 2007 Jan 3.
7
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1992-7. doi: 10.1073/pnas.0408283102. Epub 2005 Jan 27.
8
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Blood. 2003 Jan 15;101(2):690-8. doi: 10.1182/blood.V101.2.690.
Zotero 插件